PL2948156T3 - Zastosowanie soli wolframu (vi) w leczeniu niepłodności żeńskiej u nie chorujących na cukrzycę ssaków - Google Patents

Zastosowanie soli wolframu (vi) w leczeniu niepłodności żeńskiej u nie chorujących na cukrzycę ssaków

Info

Publication number
PL2948156T3
PL2948156T3 PL14701067T PL14701067T PL2948156T3 PL 2948156 T3 PL2948156 T3 PL 2948156T3 PL 14701067 T PL14701067 T PL 14701067T PL 14701067 T PL14701067 T PL 14701067T PL 2948156 T3 PL2948156 T3 PL 2948156T3
Authority
PL
Poland
Prior art keywords
mammarian
wolfram
don
disease
salt
Prior art date
Application number
PL14701067T
Other languages
English (en)
Inventor
Almazán Ignacio Canals
Bugié Agnès Arbat
Original Assignee
Oxolife Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49999950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2948156(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxolife Sl filed Critical Oxolife Sl
Publication of PL2948156T3 publication Critical patent/PL2948156T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physiology (AREA)
PL14701067T 2013-01-22 2014-01-21 Zastosowanie soli wolframu (vi) w leczeniu niepłodności żeńskiej u nie chorujących na cukrzycę ssaków PL2948156T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201330071A ES2478790B1 (es) 2013-01-22 2013-01-22 Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos
EP14701067.2A EP2948156B1 (en) 2013-01-22 2014-01-21 Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals

Publications (1)

Publication Number Publication Date
PL2948156T3 true PL2948156T3 (pl) 2017-07-31

Family

ID=49999950

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14701067T PL2948156T3 (pl) 2013-01-22 2014-01-21 Zastosowanie soli wolframu (vi) w leczeniu niepłodności żeńskiej u nie chorujących na cukrzycę ssaków

Country Status (26)

Country Link
US (1) US9675638B2 (pl)
EP (1) EP2948156B1 (pl)
JP (1) JP6045721B2 (pl)
KR (1) KR102182563B1 (pl)
CN (1) CN105188721B (pl)
AU (1) AU2014209987B2 (pl)
BR (1) BR112015017483A2 (pl)
CA (1) CA2898953C (pl)
CL (1) CL2015002047A1 (pl)
CY (1) CY1118287T1 (pl)
DK (1) DK2948156T3 (pl)
ES (2) ES2478790B1 (pl)
HR (1) HRP20161611T1 (pl)
HU (1) HUE031910T2 (pl)
IL (1) IL240062B (pl)
LT (1) LT2948156T (pl)
MX (1) MX356851B (pl)
NZ (1) NZ710583A (pl)
PL (1) PL2948156T3 (pl)
PT (1) PT2948156T (pl)
RS (1) RS55418B1 (pl)
RU (1) RU2635507C2 (pl)
SG (1) SG11201505701WA (pl)
SI (1) SI2948156T1 (pl)
SM (2) SMT201700018T1 (pl)
WO (1) WO2014114644A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551828B1 (es) * 2014-05-21 2016-09-12 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)
ES2639588B1 (es) * 2014-05-21 2018-09-06 Oxolife, S.L. Uso de una sal de tungsteno (VI) para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético
CA2955914C (en) * 2014-07-21 2022-09-06 Ignacio Canals Almazan Tungsten (vi) salts for use thereof in the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal, as well as for improving the efficacy of assisted reproductive techniques
EP4368577A1 (en) * 2022-11-08 2024-05-15 Oxolife, S.L. Process for the preparation of tungsten (vi) salt hydrates
WO2026008874A1 (en) 2024-07-05 2026-01-08 Oxolife, S.L. Tungsten (vi) salts for use for increasing ongoing pregnancies, for increasing live birth rates and/or for increasing the biochemical pregnancy rate in infertile women

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328134A (en) * 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
ES2108642B1 (es) * 1995-07-26 1998-08-16 Quimica Farm Bayer Sa Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
RU2141361C1 (ru) * 1998-03-12 1999-11-20 Пермская государственная медицинская академия Способ лечения ановуляторного бесплодия при ожирении
ES2187276B1 (es) * 2001-05-16 2004-08-01 Quimica Farmaceutica Bayer,S.A. Composiciones orales para el tratamiento de humanos obesos y no diabeticos.
AU2002368261A1 (en) * 2002-10-02 2004-04-23 Yeda Research And Development Co. Ltd. Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
RU2270684C1 (ru) * 2005-01-20 2006-02-27 Анатолий Григорьевич Гриценко Лекарственный препарат "витасорб"
WO2007014970A1 (es) * 2005-07-29 2007-02-08 Universidad De Barcelona Composiciones farmacéuticas que comprenden una sal de tungsteno (vi) para el tratamiento de trastornos neurodegenerativos, en particular alzheimer y esquizofrenia
US20060100154A1 (en) * 2005-10-13 2006-05-11 Yeda Research And Development Co Long-acting gonadotropin-releasing hormone analogs and methods of use thereof

Also Published As

Publication number Publication date
CA2898953C (en) 2018-01-02
HUE031910T2 (en) 2017-08-28
SG11201505701WA (en) 2015-08-28
JP2016505057A (ja) 2016-02-18
HRP20161611T1 (hr) 2017-01-27
IL240062A0 (en) 2015-09-24
DK2948156T3 (da) 2017-01-02
US9675638B2 (en) 2017-06-13
SMT201700018B (it) 2017-03-08
AU2014209987B2 (en) 2016-09-01
EP2948156A1 (en) 2015-12-02
EP2948156B1 (en) 2016-10-26
IL240062B (en) 2018-11-29
ES2478790A1 (es) 2014-07-22
JP6045721B2 (ja) 2016-12-14
RS55418B1 (sr) 2017-04-28
RU2635507C2 (ru) 2017-11-13
BR112015017483A2 (pt) 2017-07-11
RU2015135578A (ru) 2017-03-02
PT2948156T (pt) 2016-11-30
AU2014209987A1 (en) 2016-01-21
LT2948156T (lt) 2016-12-27
CN105188721A (zh) 2015-12-23
CN105188721B (zh) 2017-10-31
CL2015002047A1 (es) 2016-01-04
WO2014114644A1 (en) 2014-07-31
ES2478790B1 (es) 2015-05-06
CY1118287T1 (el) 2017-06-28
ES2611776T3 (es) 2017-05-10
US20150359820A1 (en) 2015-12-17
CA2898953A1 (en) 2014-07-31
KR102182563B1 (ko) 2020-11-25
SI2948156T1 (sl) 2017-02-28
SMT201700018T1 (it) 2017-03-08
HK1217442A1 (en) 2017-01-13
MX2015009364A (es) 2016-03-08
MX356851B (es) 2018-06-18
KR20150130992A (ko) 2015-11-24
NZ710583A (en) 2016-06-24

Similar Documents

Publication Publication Date Title
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
DK3022707T3 (da) Systemer og fremgangsmåder til at monitorere bevægelse af sygdomsfelt
EP3349854A4 (en) PREDICTING THE CLINICAL RESPONSE TO IL23 ANTAGONISTS WITH IL23 PATIENT BIOMARKERS
EP2845071A4 (en) THREE-DIMENSIONAL CONTROL OF QUADROCOPTER TEAMS
EP2964238A4 (en) ABCB5 (+) - STEM CELLS FOR THE TREATMENT OF EYE DISEASES
EP2994952A4 (en) THREE-DIMENSIONAL (3D) ELECTRODE ARCHITECTURE FOR MICROBATTERY
PL4374873T3 (pl) Środek do stosowania w leczeniu lub zapobieganiu schorzeniom okulistycznym
IL244492A0 (en) Broton tyrosine kinase inhibitors
EP2971141A4 (en) SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS
EP2965277A4 (en) PREDICTION OF APPROVAL OF TRANSACTIONS
EP3019491A4 (en) KINASEHEMMER FOR THE TREATMENT OF DISEASES
SG11201507459YA (en) Heterocyclic compounds useful in the treatment of disease
UA29014S (uk) Комп'ютер
GB201322094D0 (en) Methods and compositions relating to alzheimers disease
DK3089707T3 (da) Vævtransplantater og fremgangsmåder til fremstilling og brug af samme
EP2962216A4 (en) COMMON USE OF APPLICATION STATES
EP2983619A4 (en) SURGICAL GUIDANCE AND PLANNING SOFTWARE FOR SUITABILITY TREATMENT
EP2953948A4 (en) FLUORINATED INTEGRIN ANTAGONISTS
EP2974360A4 (en) BEHIND THE EAR BEARING HEADPHONES
EP3003140C0 (en) ELECTROCARDIOGRAM ANALYSIS
EP2851041A4 (en) Toe separator pad
EP2982364A4 (en) OIL-IN-WATER EMULSION COMPOUND
EP3397146A4 (en) CARDIO-KINETIC CROSS-SPECTRAL DENSITY FOR THE EVALUATION OF SLEEP PHYSIOLOGY
FR3013056B1 (fr) Procede de preparation d'une graisse sulfonate de calcium complexe
GB201310150D0 (en) Methods and compositions relating to alzheimer's disease